SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company, has announced the transition of TLANDO's commercialization to Verity Pharma. TLANDO, an oral testosterone replacement therapy (TRT) approved by the FDA, is now being marketed in the U.S. by Verity Pharma as of Thursday.
TLANDO is recognized for its unique attribute of not requiring dose titration, a process often necessary for testosterone therapies. This therapy is designed for adult males with conditions related to a deficiency or absence of endogenous testosterone.
The transition to Verity Pharma follows an exclusive licensing agreement with Gordon Silver Limited, finalized in January 2024, which granted the marketing rights of TLANDO in the United States and potentially Canada. Lipocine received a $5 million tranche of the $11 million licensing fee as part of this agreement, with additional payments of $2.5 million and $1 million due by January 1, 2025, and January 1, 2026, respectively.
Lipocine's proprietary Lip'ral drug delivery technology platform was utilized in the development of TLANDO, which has been on the market since its initial U.S. approval in 1953. However, the company warns of potential blood pressure increases with TLANDO use, which may elevate the risk of major adverse cardiovascular events, especially in patients with cardiovascular disease or risk factors.
The information in this article is based on a press release statement from Lipocine Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.